Human challenge trials (HCTs) have the potential to lay
groundwork for critical advances in medicine. For centuries,
physicians and researchers have intentionally infected
human subjects to study disease transmission and design
life-saving vaccines and treatments. Historically, many
controlled infections occurred without informed consent
from participants, but in the last century, several HCTs
have been conducted which included full risk assessment,
informed consent, and patient compensation. The COVID-19
pandemic has elevated the topic of establishing human
challenge trials to accelerate the design and testing of
protective vaccines. Thousands of people have expressed
willingness to be infected with SARS-CoV-2, risking their
health to help the global effort of ending the pandemic.
Conducting such a study during a pandemic involves
additional scientific and ethical precautions to minimize the
risk to volunteers and to prevent community transmission;
however, HCTs are not directly regulated. Here, we
assess the scientific, ethical, and regulatory considerations
of implementing HCTs for infectious disease models,
particularly in pandemic settings.